ACTIVATE

Already have a savings card?

Activate Now ›

Already Registered?

Log In Now › to update your reminders, access materials and more.

Alcon reserves the right to revoke or ame
and to deny payment for noncompliance
expires June 30, 2016, unless this offer is
Use of this savings card is subject to app
void where prohibited. In the event an A
becomes available for one of the product
offer will become void in Massachusetts

Eligibility:

By using the OPENINGS® Program savi
currently meet the following eligibility crite

- You have a valid prescription for T
SIMBRINZA® Suspension, or AZO
- You have no insurance or are subj
requirement for your prescription;
- **You are not enrolled in Medicare
DOD, Tricare, or any other gover
sponsored health care program**
- No purchase is necessary and the
- You are at least 18 years old; and
- You reside in the United States.

Minimum out-of-pocket expenses and

Eligible commercially insured patients are
expenses noted below and any amount t
each prescription, as follows:

- For a 30-day supply (2.5 mL of TR
SIMBRINZA® Suspension or 10 m
$25 out of pocket and Alcon will pa
- For a 60-day supply (5 mL of TRA
SIMBRINZA® Suspension or 15-25
patient pays $50 out of pocket and
remaining balance.
- For a 90-day supply (7.5 mL of TR
SIMBRINZA® Suspension or 30 m
$50 out of pocket and Alcon will pa

Eligible uninsured cash paying patients s
the usual and customary retail price, as f

- For a 30-day supply (2.5 mL of TR
SIMBRINZA® Suspension, or 10 m
save up to $60 on actual out-of-po
price

that you understand the program rules, re
and that you will comply with them. You r
your insurer. You are responsible for any
required by your insurer. If you have any
Program at (866) 972-3008.

Pharmacist Instructions for a Patient v

When you use this card, you are certifyin
not submit a claim for reimbursement unc
or government sponsored health care pro
primary coverage exists, input card inform
transmit using the COB segment of the N
to McKesson Corporation using BIN #610
displayed in the transaction response. Ac
submission of claims are also subject to t
www.mckesson.com/mprstnc.

Pharmacist Instructions for an Uninsu

For uninsured cash-paying patients, subr
Corporation using BIN #610524. Accepta
transaction response. Acceptance of this
also subject to the Terms and Conditions
www.mckesson.com/mprstnc.

**For questions regarding setup, claim t
other issues, call the LoyaltyScript® fo
8027 (8:00 AM-8:00 PM EST, Monday-F
Alcon reserves the right to rescind, re**

Important information about TRAVATAN Z® (travoprost ophthalmic solution) 0.004%

INDICATIONS AND USAGE

TRAVATAN Z® Solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosing and Administration

The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z® Solution should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP lowering effect.

TRAVATAN Z® Solution may be used

Important information about SIMBRINZA® (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%

INDICATIONS AND USAGE

SIMBRINZA® Suspension is a fixed combination indicated in the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosage and Administration

The recommended dose is one drop of SIMBRINZA® Suspension in the affected eye(s) three times daily. Shake well before use SIMBRINZA® Suspension may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being

lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Intraocular Inflammation - TRAVATAN Z® Solution should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Macular Edema - Macular edema, including cystoid macular edema, has been reported during treatment with travoprost ophthalmic solution. TRAVATAN Z® Solution should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Angle-closure, Inflammatory or Neovascular Glaucoma - TRAVATAN Z® Solution has not been evaluated for the treatment of angle-closure, inflammatory or neovascular glaucoma.

Bacterial Keratitis - There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial.

Use with Contact Lenses - Contact lenses should be removed prior to instillation of TRAVATAN Z® Solution and may be reinserted 15 minutes following its administration.

Adverse Reactions

The most common adverse reaction observed in controlled clinical studies with TRAVATAN Z® Solution was ocular hyperemia which was reported in 30 to 50% of patients. Up to 3% of patients discontinued therapy due to conjunctival hyperemia. Ocular adverse reactions reported at an incidence of 5 to 10% in these clinical studies included decreased visual acuity, eye discomfort, foreign body

is not recommended.

Acute Angle-Closure Glaucoma—The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. SIMBRINZA® Suspension has not been studied in patients with acute angle-closure glaucoma.

Contact Lens Wear—The preservative in SIMBRINZA® Suspension, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of SIMBRINZA® Suspension but may be reinserted 15 minutes after instillation.

Severe Cardiovascular Disease—Brimonidine tartrate, a component of SIMBRINZA® Suspension, had a less than 5% mean decrease in blood pressure 2 hours after dosing in clinical studies; caution should be exercised in treating patients with severe cardiovascular disease.

Potentiation of Vascular Insufficiency—Brimonidine tartrate, a component of SIMBRINZA® Suspension, may potentiate syndromes associated with vascular insufficiency. It should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or Thromboangiitis obliterans.

Contamination of Topical Ophthalmic Products After Use—There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers have been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Adverse Reactions

SIMBRINZA® Suspension

incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocula allergic reactions, and ocular pruritus.

Events occurring in approximately 3-9% of the subjects, in descending order, included cornea staining/erosion, photophobia, eyelid erythema ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision, and muscular pain.

Drug Interactions—Consider the following when prescribing SIMBRINZA® Suspension

Concomitant administration with oral carbonic anhydrase inhibitors is not recommended due to the potential additive effect. Use with high-dose salicylate may result in acid-base and electrolyte alterations. Use with CNS depressants may result in an additive or potentiating effect. Use with antihypertensives/cardiac glycosides may result in additive or potentiating effect on lowering blood pressure. Use with tricyclic antidepressants may blunt the hypotensive effect of systemic clonidine and it is unknown i use with this class of drugs interferes with IOP lowering. Use with monoamine oxidase inhibitors may result in increased hypotension.

Click here for full prescribing information for SIMBRINZA® Suspension

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.